Eyeing pair of amyloidosis indications, AZ in deal for Ionis asset

AstraZeneca’s deal with Ionis gives the pharma rights to a next-generation amyloidosis therapy in late-stage testing for two forms of the disease: one that manifests as polyneuropathy, and the other as cardiomyopathy.

For $200 million up front, AstraZeneca plc (LSE:AZN; NYSE:AZN) will share U.S. rights with Ionis Pharmaceuticals Inc. (NASDAQ:IONS) to eplontersen (IONIS-TTR-LRX), an antisense oligo in the Phase III NEURO-TTRansform and CARDIO-TTRansform trials for the two forms of TTR amyloidosis (ATTR). AstraZeneca will gain all ex-U.S. rights, excluding Latin America...